|1.||Hatch, Grant M: 2 articles (01/2014 - 03/2006)|
|2.||Houtkooper, Riekelt H: 2 articles (08/2013 - 04/2009)|
|3.||Wanders, Ronald J: 2 articles (08/2013 - 04/2009)|
|4.||McMaster, Christopher R: 1 article (04/2015)|
|5.||Gaspard, Gerard J: 1 article (04/2015)|
|6.||Mejia, Edgard M: 1 article (01/2014)|
|7.||Cole, Laura K: 1 article (01/2014)|
|8.||Manfredi, Giovanni: 1 article (08/2013)|
|9.||Bellenguer, Pascale: 1 article (08/2013)|
|10.||Moustapha, Aoula: 1 article (08/2013)|
01/01/2009 - "The genetic disorder Barth syndrome (BTHS) is caused by mutations in the tafazzin gene resulting in decreased total CL levels, accumulation of monolysocardiolipin (MLCL), and decreased unsaturated fatty acyl species of CL. "
10/01/2006 - "Monolysocardiolipin in cultured fibroblasts is a sensitive and specific marker for Barth Syndrome."
01/01/2014 - "This resynthesis of deacylated cardiolipin from monolysocardiolipin occurs via the Barth Syndrome gene product tafazzin and acyllysocardiolipin acyltransferase-1, monolysocardiolipin acyltransferase-1 and the alpha subunit of trifunctional protein. "
04/15/2009 - "Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome."
03/01/2006 - "Mutations in TAZ result in a decrease in tetra-linoleoyl species of cardiolipin and an accumulation of monolysocardiolipin within cells from Barth Syndrome patients. "
04/03/2015 - "Mutations in human TAZ cause Barth syndrome, a fatal childhood cardiomyopathy biochemically characterized by reduced cardiolipin mass and increased monolysocardiolipin levels. "
08/01/2013 - "In Barth syndrome, an X chromosome-linked cardiomyopathy caused by tafazzin mutations, cardiolipins display acyl chain modifications and are present at abnormally low concentrations, whereas monolysocardiolipin accumulates. "
|2.||Messenger RNA (mRNA)